Cardiovascular, Metabolic and Endocrine Diseases (CVMED)

Chronic cardiovascular disease and diabetes cause one of every three deaths in the world today. Unless breakthroughs are made, the growing prevalence of diabetes and obesity will greatly add to the human and economic cost of disease over the next 20 years. Advances in understanding risk factors and in the development of new therapies have demonstrated that cardiovascular disease is largely preventable. Pfizer's current and future portfolio of medicines in this Therapeutic Area focuses on the control of the risk factors inherent in smoking, diet, physical inactivity, and Type 2 diabetes. We are also dedicated to discovering and developing medicines to treat Obesity, Atherosclerosis, Thrombosis, Bone Health, and Muscle Health.

Cardiovascular, Metabolic and Endocrine Diseases (CVMED)

Indications for medicines currently in phases of development, from Phase 1 through recent approval:

• Atherosclerosis – A process of plaque build-up in arteries that may partially or totally block the blood's flow through an artery, which can result in a heart attack or stroke. This process is accelerated in dyslipidemia, diabetes, hypertension, and obesity.
• Bone Health – Conditions that affect bone mass, density and strength of weakened bones. We seek medicines to improve bone health and speed the healing of fractured bones.
• Diabetes – A disease in which the body's production of or sensitivity to insulin is impaired, leading to poor control of blood sugar levels. Diabetes may eventually lead to other diseases and conditions, including cardiovascular disease and kidney failure. The global prevalence of diabetes is on the increase and is closely tied to the rising rates of obesity.
• Muscle Health – Medicines to aid in the strength and function of skeletal muscle in such disease states as diabetes, muscle-related diseases and age-related muscle decline and frailty.
• Obesity – Usually defined as someone who is more than 20 percent above what is considered a healthy weight for their height, age and bone structure. Obesity is on the increase across the world, and it significantly raises the risk that patients may acquire other diseases leading to premature death. Our pipeline of new medicines contains a variety of different approaches. The successful treatment of obesity may come from the co-administration of agents across this spectrum of approaches.
• Osteoporosis – A decrease in bone mass, density, and strength that can lead to frailty.
• Thrombosis – The formation of a clot (thrombus) in an artery or vein restricting blood flow. Arterial thrombosis is often caused by atherosclerosis and may lead to systemic embolism and stroke. Venous thrombosis may lead to deep venous thrombosis and pulmonary embolism.

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.